American Association for Cancer Research
10559965epi141351-sup-142000_1_supp_2941619_nmwq46.doc (10 kB)

Supplementary Figure 1 caption from Circulating 25-Hydroxyvitamin D3 and Survival after Diagnosis with Kidney Cancer

Download (10 kB)
journal contribution
posted on 2023-03-31, 14:02 authored by David C. Muller, Ghislaine Scelo, David Zaridze, Vladimir Janout, Ivana Holcatova, Marie Navratilova, Dana Mates, Øivind Midttun, Per Magne Ueland, Paul Brennan, Mattias Johansson

Supplementary Figure 1 caption



Prospective cohort studies have provided some evidence that circulating vitamin D is associated with risk of, and survival from, renal cell carcinoma (RCC), but it is unclear whether concentrations of vitamin D at the time of diagnosis of RCC are associated with prognosis. We conducted a case–cohort study of 630 RCC cases, including 203 deaths, from a multicenter case–control study in Eastern Europe. Vitamin D was assessed as 25-hydroxyvitamin D3 [25(OH)D3], and we used weighted Cox models to estimate hazard ratios (HR) and 95% confidence intervals (CI) by categories of season-adjusted 25(OH)D3. Higher concentrations of 25(OH)D3 were associated with lower risk of death after adjusting for stage, age, sex, and country (HR highest vs. lowest category 0.57; 95% CI, 0.34–0.97). The inverse associations of 25(OH)D3 with death were most notable among those who died from non-RCC causes and those diagnosed with early-stage disease. In summary, 25(OH)D3 concentration at diagnosis of RCC was inversely associated with all-cause mortality rates, but not specifically with RCC outcome. Cancer Epidemiol Biomarkers Prev; 24(8); 1277–81. ©2015 AACR.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention



    Ref. manager